(Q37483961)

20 August 2017

1 reference

title

Current systemic therapy for metastatic melanoma (English)

1 reference

20 August 2017

1 reference

1 reference

Sanjiv S Agarwala

1

1 reference

20 August 2017

1 May 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

587-595

1 reference

20 August 2017

5

1 reference

20 August 2017

Cancer statistics, 2008

1 reference

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

21 January 2018

1 reference

Phase II study of paclitaxel and carboplatin for malignant melanoma

21 January 2018

1 reference

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

21 January 2018

1 reference

The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.

21 January 2018

1 reference

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

21 January 2018

1 reference

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients

21 January 2018

1 reference

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy

21 January 2018

1 reference

Enhanced expression of vascular endothelial growth factor in metastatic melanoma

21 January 2018

1 reference

Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo

21 January 2018

1 reference

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic melanoma

21 January 2018

1 reference

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

Treatment of germ cell tumors--update 2006.

21 January 2018

1 reference

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.25

1 reference

20 August 2017

1 reference

PubMed ID

19445576